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Background: The purpose of our study is to assess practices of North American pediatric rheumatologists
regarding monitoring, prevention, and treatment of low bone mineral density (BMD) in children on long-term
glucocorticoid treatment.
Long-term glucocorticoid therapy is associated with accelerated bone loss. Children with JIA and lupus have low
baseline BMD and incident vertebral fractures commonly occur in these groups of patients even after a relatively
short period of time being on systemic glucocorticoids. There are no established guidelines for identification,
prevention, and treatment of glucocorticoid-induced bone loss in children.
Methods: A cross-sectional online survey was conducted with 199 physicians who were listed in the ACR database
as practicing pediatric rheumatology in North America.
Results: 86 physicians (43%) responded; 87% were board-certified in pediatric rheumatology. 95% used dual energy
X-ray absorptiometry as their primary modality for assessing BMD. 79% “rarely” or “never” obtained a baseline BMD
measurement prior to initiation of glucocorticoid therapy. 42% of respondents followed BMD annually. 93% “frequently”
or “always” prescribed calcium for patients on long-term corticosteroid therapy; 81% “frequently” or “always” prescribed
vitamin D. In patients diagnosed with osteoporosis, 35%-50 % of the practitioners “sometimes”, “frequently” or “always”
prescribed bisphosphonates. Bisphosphonates are prescribed at similar rates for male and female patients, and slightly
more frequently for pubertal than for pre-pubertal patients. 96% of respondents “rarely” or “never” prescribed calcitonin
for patients on long-term glucocorticoid therapy; 92% “rarely” or “never” prescribe this medication for patients with
known osteopenia or osteoporosis.
Conclusions: Utilization of DXA in children on long-term corticosteroid therapy varies greatly among North American
pediatric rheumatologists. Most respondents do not screen for low BMD on a regular basis despite acknowledging
the risks of bone loss in this population. Broad consensus appears to be present among practitioners favoring
the prescription of calcium and vitamin D for patients receiving long-term corticosteroid therapy. Relatively few
respondents consistently recommend bisphosphonate therapy, even for patients with known low bone density;
calcitonin is rarely used. These data underscore the need for studies to acquire specific data on bone loss, and its
prevention and treatment in young patients on long-term glucocorticoid therapy.
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Long-term glucocorticoid therapy is known to be asso-
ciated with accelerated bone loss, causing increased risk
of osteoporosis and fracture [1]. Low bone density is
common in juvenile idiopathic arthritis (JIA), lupus and
other pediatric rheumatologic diseases [2-7]. Many patients
with JIA have low BMD, even at baseline before the start of
systemic glucocorticoid treatment. 30% of mildly to moder-
ately ill pre-pubertal JIA patients who had never been
treated with corticosteroids had low total body BMD [8].
Asymptomatic vertebral fractures are an under-recognized
problem in children with inflammatory disorders and can
be present prior to prolonged glucocorticoid exposure in
pediatric rheumatology patients [9,10].
The ACR has published clinical guidelines for diagnosis
and management of osteoporosis for adults on long-term
glucocorticoid therapy [11]. Despite guidelines, some stud-
ies show that many patients treated with glucocorticoids do
not receive any treatment to prevent bone loss [12,13].
A recent survey of adult rheumatologists revealed signifi-
cant variability in corticosteroid – induced osteoporosis
management [14]. There is even less experience on this
medical issue in pediatrics, as there are no established
clinical guidelines for identification and prevention of
glucocorticoid-induced bone loss in children. Further-
more, once the diagnosis of osteopenia/osteoporosis is
established in children, treatment options are limited and
poorly studied.
There are several studies reporting that bisphospho-
nates are safe and effective in children [15-21]. However,
there are still concerns among pediatric rheumatologists
about the long-term effects of bisphosphonate use in
children. Pediatric rheumatologists hesitate to prescribe
bisphosphonates to children because the possible long-
term adverse effects, the necessary length of treatment
and the maximal bone mass gain that can be achieved in
children are all unknown.
With this survey, we aimed to assess current practices
of North American pediatric rheumatologists regarding
monitoring, prevention, and treatment of osteoporosis
and osteopenia in children on long-term glucocorticoid
treatment.Methods
Sample population
Using electronic mail, an online, self-administered survey
was sent to 199 physicians practicing pediatric rheuma-
tology in North America. Physicians were surveyed
using a questionnaire probing the diagnosis, prevention,
treatment, and monitoring of osteoporosis in children
receiving long-term oral systemic corticosteroid therapy.
Ethics approval was granted by the University of Chicago
Institutional Review Board.Survey design
The survey was comprised of 17 items (see Additional
file 1). It addressed three major themes in management
of glucocorticoid-induced osteoporosis in children: 1)
Preferred methods of diagnosis 2) Current approaches to
prevention 3) Preferred treatment choices.Analysis
Data analysis included descriptive statistics applied to the
closed-ended questions, expressed as frequency (percent-
ages) for categorical variables.Results
86 of the 199 physicians who were sent the survey com-
pleted the survey (43% response rate), of which 85%
were board certified to practice pediatric rheumatology in
the US. 84% of the respondents were pediatric rheumatol-
ogists, 10% were medicine/pediatric rheumatologists, 1%
pediatric rheumatology fellow, 1% adult rheumatologist,
and 4% listed themselves as “other”. The most common
practice setting, with 86%, was an “Academic Medical
Center”. 5% of the respondents practiced at a community
hospital, 5% in private practice, and 4% reported their
practice setting as “other”.
46% of the physicians reported that they would consider
measures to identify or prevent corticosteroid-induced
bone loss in patients treated with any steroid dose. 31%
would consider such measures only at prednisone doses
greater than 0.5 mg/kg/day, 17% at doses greater than 1
mg/kg/day, 5% at doses greater than 2 mg/kg/day.
80% of the physicians never or rarely obtained a baseline
BMD measurement, by any method, before initiating
long-term (>6 months) glucocorticoid treatment; 11% did
so sometimes, 7% frequently. Only 2% of the physicians
always obtained a baseline measurement before initiating
long-term glucocorticoid treatment.
The most commonly used tool for initial BMD meas-
urement and to monitor steroid-related bone loss was
DXA (96%); 4% of the physicians used quantitative CT,
and none of the responders used quantitative ultrasound
of bone or single X-ray absorptiometry of bone for these
purposes. 5% of the physicians obtained follow-up BMD
measurements every 6 months, 42% annually, 5% every
18 months, and 16% less frequently than every two
years. 2% never obtained follow-up BMD measurements.
Only 6% of physicians reported having a written policy
in their department regarding the frequency of BMD
measurements in children on long-term glucocorticoid
treatment.
93% of the physicians reported starting calcium supple-
ments frequently or always for patients who are on long-
term corticosteroid treatment. Vitamin D supplements
were given frequently or always by 80% of physicians.
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In patients diagnosed with either osteopenia or osteo-
porosis, between 35% and 50% of the practitioners
“sometimes”, “frequently” or “always” prescribed bispho-
sphonates. Bisphosphonates are prescribed at similar
rates for male and female patients, and slightly more
frequently for pubertal than for pre-pubertal patients.
96% of respondents “rarely” or “never” prescribe calcitonin
for patients on long-term glucocorticoid therapy, and 92%
“rarely” or “never” prescribe this medication for patients
with known osteopenia or osteoporosis.
Discussion
Low bone density is common in children with JIA, lupus
and other rheumatologic diseases [2-5]. 30% of mildly to
moderately ill pre-pubertal JIA patients who had never
been treated with corticosteroids had low total body
BMD [8]. Patients with juvenile SLE have a low bone mass
without catch-up growth over time, causing a reduction
of peak bone mass with high risk of osteoporosis in
early adulthood [7]. Local inflammatory factors, decreased
physical activity, nutritional imbalances, and medications
have all been implicated in bone loss [22,23]. In our study,
many physicians (46%) reported that they would consider
measures to identify or prevent corticosteroid-induced
bone loss at any steroid dose. However, the preponderance
(80%) of the physicians never or rarely obtained a baseline
BMD measurement, by any method, before initiating
long-term (>6 months) glucocorticoid treatment.
Vertebral fractures are an under-recognized problem
in children with inflammatory disorders and they can be
present prior to prolonged glucocorticoid exposure. A
recent study reported that the incidence of vertebral
fractures in children with rheumatologic diseases in the
12 months following glucocorticoid initiation was 6%,
and most children were asymptomatic [10]. Another
study on children with rheumatic conditions reported
that 7% of children had vertebral fractures within 30
days of initiating glucocorticoids [9]. Studies in adults
have shown that patients with glucocorticoid-induced
osteoporosis experience fragility fractures at better DXA
scores than those with postmenopausal or age-related
osteoporosis. This might be explained, at least in part,
by the effects of glucocorticoids not only on osteoclasts
but also on osteoblasts and osteocytes [24]. Therefore,
prevention and early diagnosis of low bone density is
important in pediatric rheumatology patients to prevent
fragility fractures.
Per the guidelines published by The International Society
for Clinical Densitometry in 2013, in the absence of
vertebral compression (crush) fractures, the diagnosis
of osteoporosis in children is indicated by the presence
of both a clinically significant fracture history andBMD Z-score ≤ -2.0. The Society stresses that diagnosis
of osteoporosis in children and adolescents should not
be made on the basis of densitometric criteria alone.
However, they recommend that in patients with primary
bone disease, or at risk for a secondary bone disease, a
DXA should be performed when the patient may benefit
from interventions to decrease their elevated risk of a
clinically significant fracture, and the DXA results will
influence that management. Per these guidelines, DXA
is the preferred method for assessing BMC and areal
BMD in children. Despite the data showing the high
frequency of asymptomatic fragility fractures in children
with rheumatologic diseases who are on long-term gluco-
corticoids and recommendations by The International
Society for Clinical Densitometry summarized above,
we found in our study that only 42% of the physicians
obtained follow-up BMD measurements annually to
screen for low bone density in patients who are on
long-term glucocorticoid treatment. Few physicians (only
6%) had a written policy in their department regarding
the frequency of BMD measurements in children on
long-term glucocorticoid treatment.
In our study, DXA was the most commonly utilized
diagnostic tool for diagnosis and follow-up of glucocortic-
oid-induced osteoporosis. None of the physicians who
responded to our survey reported using bone ultrasound
to monitor bone health in pediatric rheumatology patients
who were on long-term glucocorticoid treatment. How-
ever, there is a growing body of evidence regarding the use
of bone ultrasound in children to monitor bone density.
Quantitative ultrasound (QUS) can be used for radiation-
free assessment of bone density and “bone quality” by
measurement of the ultrasound wave attenuation by
bone (BUA) in children with JIA. Bone speed of sound
(SOS) shows a significant correlation with BMD as mea-
sured by DXA. Portability, ease of use, lower cost, and
absence of radiation make QUS of bone a promising
means of evaluating BMD in children [25-31].
As stated earlier, there are no guidelines for prevention
or treatment of glucocorticoid-induced osteoporosis in
children. In our study, 93% of the physicians reported
starting calcium supplements frequently or always as a
preventative measure for patients who are on long- term
corticosteroid treatment. Vitamin D supplements were
given always or frequently by 80% of the respondents. In
our study, 62% and 49% of the physicians never or rarely
prescribed bisphosphonates for their pre-pubertal and
pubertal female patients, respectively, with documented
osteoporosis; 60% and 50% of the physicians never or
rarely prescribed bisphosphonates for their pre-pubertal
and pubertal male patients. A possible reason for its
limited use in pediatrics is the concern of long-term side
effects related to the persistence of bisphosphonates in
bone. However, only bone tissue appears to be affected
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bone ensures that the other tissues are exposed for only
a short period to these drugs (the half-life of circulating
bisphosphonates in humans is 0.5-2 hours), and as far as
we know, there is no evidence that bisphosphonates
maintain any pharmacologic activity once sequestered in
the bone [32]. In a prospective multicenter study, oral
alendronate was found to be safe and efficacious for the
treatment of osteoporosis in diffuse connective tissue
diseases in children [15]. Several other studies to date
have shown safety and efficacy of bisphosphonates in
children [15,21,33,34]. Most commonly reported adverse
effects included acute phase type of reactions and flu-
like reactions (fever, muscle aches, bone pain) with IV
infusion of bisphosphonates which usually responds to
acetaminophen or ibuprofen and did not usually occur
with further infusions [35-38]. Self-limited mild abdom-
inal pain, nausea, and vomiting after the first infusion of
bisphosphonates have also been reported [35]. Transient
decreases in serum calcium and phosphate levels after
treatment with intravenous pamidronate have been re-
ported [16,17,39-41].
Several studies reported normal growth during treat-
ment with bisphosphonates [15,36,37,42]. Metaphyseal
banding (zebra lines) can be seen on the radiographs
of children receiving cyclical bisphosphonate therapy
[43]. The linear growth was found to be normal in sev-
eral studies after use of bisphosphonates in children
[17,44-46]. There were no effects of commonly used
bisphosphonates on the growth plate and bone ages of
children corresponded with their chronological age
[17]. Bisphosphonate-associated osteonecrosis of the
jaw has been reported in adults, but no cases have
been reported in children so far [47].
There is a hesitance to use bisphosphonates in girls and
young women of childbearing age due to concerns for
potential unfavorable effects of bisphosphonate treatment
on the fetus, mainly in the skeleton. Since bisphospho-
nates are retained for a long time in the human skeleton,
concerns have been raised that even pre-pregnancy
administration of bisphosphonates may result in embryo-
fetal exposure and alter fetal bone modeling.
A recent study reviewed fifty-one cases of exposure to
bisphosphonates before or during pregnancy; none of
the pregnancies resulted in skeletal abnormalities or other
congenital malformations in the infants [48].
Considering the high incidence of vertebral fractures
in children on chronic glucocorticoid treatment and the
data supporting safety and efficacy of bisphosphonates
in children in general, it can be argued that the benefits
of bisphosphonate therapy may outweigh the potential
risks in patients with low bone density and frequent
fragility fractures. Therefore, bisphosphonates should be
considered as a treatment option for children who are onlong-term glucocorticoid treatment and have documented
osteopenia/osteoporosis.
Calcitonin is a naturally occurring peptide, which inhibits
bone resorption by osteoclasts, and is useful for treatment
of osteoporosis, reducing vertebral and hip fractures in
adult patients. It is usually well tolerated, and its main
side-effects are gastrointestinal. It can be administered by
injection, orally or intranasally. Calcitonin has been shown
to be safe and effective in treatment of steroid-induced
osteoporosis in children with nephrotic syndrome [49].
Another recent study of intranasal calcitonin in 10 children
with JIA showed a decrease in bone resorption markers
and an increase in BMD [50]. Also, calcitonin can rapidly
improve symptoms of vertebral fractures [51]. However,
because the evidence is limited on the use of calcitonin in
children, pediatric rheumatologists infrequently utilize it.
96% of respondents reported “rarely” or “never” prescribing
calcitonin for patients on long-term glucocorticoid therapy,
and 92% “rarely” or “never” prescribe this medication even
for patients with known osteopenia or osteoporosis. More
studies are needed in this area.
Conclusions
Broad consensus appears to be present among North
American pediatric rheumatologists favoring the prescrip-
tion of calcium and vitamin D for pediatric patients on
long-term corticosteroid therapy.
Despite the data showing the high incidence of osteo-
porosis and incident vertebral fractures in children on
long-term glucocorticoids, relatively few respondents
consistently recommend bisphosphonate therapy, even
for patients with known osteopenia or osteoporosis,
and calcitonin is rarely used. Furthermore, there is high
variability of utilization of DXA in children on long-term
corticosteroid treatment. These data underscore the need
for more research on bone loss, and its prevention and
treatment in young patients on long-term glucocorticoid
therapy.
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